Mei-Chun Hsiao

Mei-Chun Hsiao

Auto-generated profile, based on publicly available information

Mei-Chun Hsiao

Yong Mei Psychiatric Clinic, Taoyuan City, Taiwan

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 December 2009 in Asian-Australasian Journal of Animal Sciences
Verified
Journal Article
Open access
PDF file
HLH. C. Liu
H. C. Liu
MHM. C. Hsiao
M. C. Hsiao
YHY. H. Hu
Y. H. Hu
SLS. R. Lee
S. R. Lee
WCWenjie Cheng
Wenjie Cheng

1 January 2018 in Neuropsychiatric Disease and Treatment
Verified
Journal Article
Open access
PDF file
CCChing Yen Chen
Ching Yen Chen
TTTze-Chun Tang
Tze-Chun Tang
TCTzu-Ting Chen
Tzu-Ting Chen
YBYa Mei Bai
Ya Mei Bai
HTHuei-Huang Tsai
Huei-Huang Tsai
TSTung-Ping Su
Tung-Ping Su
Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists' judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg. Eligibility considerations included lack of efficacy, tolerability, and/or adherence to previous oral antipsychotic medication. Results: Of the 297 enrolled patients, 178 (59.5%) completed the study. The main reasons for discontinuation included insufficient efficacy (8.7%), patient decision (8.4%), and adverse events (AEs; 6.4%). Improvements in the: Positive and Negative Syndrome Scale total score and Clinical Global Impression-Severity score were observed only in patients treated at medical centers and not in those treated at psychiatric hospitals. The most common AEs were insomnia, headache, constipation, and extrapyramidal syndrome. One or more serious AEs were reported in 11 (3.7%) patients; none resulted in death. No significant changes in body weight, plasma glucose, or lipid levels were observed. Conclusion: Switching to paliperidone ER was effective and well tolerated for up to 24 weeks in patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. The observed differences in treatment between psychiatric hospitals and medical centers with regard to dosage and titration of paliperidone ER warrant further investigation.